S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

Lannett (LCI) Stock Forecast, Price & News

+0.07 (+14.89%)
(As of 05/13/2022 06:40 PM ET)
Today's Range
50-Day Range
52-Week Range
438,600 shs
Average Volume
407,700 shs
Market Capitalization
$23.19 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive LCI News and Ratings via Email

Sign-up to receive the latest news and ratings for Lannett and its competitors with MarketBeat's FREE daily newsletter.

Lannett logo

About Lannett

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.


StockNews.com Begins Coverage on Lannett (NYSE:LCI)
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Sales & Book Value

Annual Sales
$478.78 million
Cash Flow
$1.29 per share
Book Value
($3.70) per share


Net Income
$-363.48 million
Pretax Margin




Free Float
Market Cap
$23.19 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.46 out of 5 stars

Medical Sector

165th out of 1,403 stocks

Pharmaceutical Preparations Industry

64th out of 667 stocks

Analyst Opinion: 3.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -

Lannett (NYSE:LCI) Frequently Asked Questions

Is Lannett a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lannett in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Lannett stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LCI, but not buy additional shares or sell existing shares.
View analyst ratings for Lannett
or view top-rated stocks.

Are investors shorting Lannett?

Lannett saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 5,740,000 shares, a drop of 14.5% from the April 15th total of 6,710,000 shares. Based on an average daily trading volume, of 437,800 shares, the days-to-cover ratio is presently 13.1 days. Currently, 17.5% of the company's stock are short sold.
View Lannett's Short Interest

When is Lannett's next earnings date?

Lannett is scheduled to release its next quarterly earnings announcement on Wednesday, August 24th 2022.
View our earnings forecast for Lannett

How were Lannett's earnings last quarter?

Lannett Company, Inc. (NYSE:LCI) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.02. The business had revenue of $101.53 million for the quarter, compared to analyst estimates of $98.62 million. Lannett had a negative trailing twelve-month return on equity of 31.06% and a negative net margin of 84.91%. During the same period last year, the company posted $0.06 EPS.
View Lannett's earnings history

What guidance has Lannett issued on next quarter's earnings?

Lannett updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $335.00 million-$350.00 million, compared to the consensus revenue estimate of $348.67 million.

What price target have analysts set for LCI?

1 Wall Street analysts have issued 1 year price objectives for Lannett's shares. Their forecasts range from $6.00 to $6.00. On average, they expect Lannett's stock price to reach $6.00 in the next year. This suggests a possible upside of 1,011.1% from the stock's current price.
View analysts' price targets for Lannett
or view top-rated stocks among Wall Street analysts.

Who are Lannett's key executives?
Lannett's management team includes the following people:
  • Mr. Timothy C. Crew, CEO & Director (Age 61, Pay $1.03M) (LinkedIn Profile)
  • Mr. John Kozlowski, VP of Fin., CFO & Principal Accounting Officer (Age 50, Pay $531.84k) (LinkedIn Profile)
  • Mr. John M. Abt, VP and Chief Quality & Operations Officer (Age 57, Pay $444.74k)
  • Mr. Samuel H. Israel, Gen. Counsel & Chief Legal Officer (Age 60, Pay $521.95k)
  • Ms. Maureen M. Cavanaugh, Sr. VP & Chief Commercial Operations Officer (Age 63, Pay $571.28k)
  • Ms. Kristie Stephens, Chief Compliance Officer & VP of Regulatory Affairs
  • Mr. Grant Brock, VP of Operations
What is Timothy Crew's approval rating as Lannett's CEO?

9 employees have rated Lannett CEO Timothy Crew on Glassdoor.com. Timothy Crew has an approval rating of 28% among Lannett's employees. This puts Timothy Crew in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lannett own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lannett investors own include (CELG), Akorn (AKRX), Skechers U.S.A. (SKX), Integrated Device Technology (IDTI), Bank of America (BAC), Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), Rite Aid (RAD) and NVIDIA (NVDA).

What is Lannett's stock symbol?

Lannett trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."

Who are Lannett's major shareholders?

Lannett's stock is owned by a variety of institutional and retail investors. Top institutional investors include Telemus Capital LLC (17.18%), JPMorgan Chase & Co. (6.08%), Renaissance Technologies LLC (5.36%), LSV Asset Management (2.83%), Vanguard Group Inc. (1.52%) and Staley Capital Advisers Inc. (1.08%). Company insiders that own Lannett stock include David A Drabik, Jeffrey Farber, John Abt, John C Chapman, John Kozlowski, Patrick G Lepore, Patrick G Lepore, Samuel H Israel and Timothy C Crew.
View institutional ownership trends for Lannett

Which major investors are selling Lannett stock?

LCI stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Dimensional Fund Advisors LP, LSV Asset Management, Wolverine Asset Management LLC, JPMorgan Chase & Co., Simplex Trading LLC, Bank of Montreal Can, and Northern Trust Corp.
View insider buying and selling activity for Lannett
or view top insider-selling stocks.

Which major investors are buying Lannett stock?

LCI stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC, Assenagon Asset Management S.A., Staley Capital Advisers Inc., First Quadrant LLC CA, GSA Capital Partners LLP, Telemus Capital LLC, and Values First Advisors Inc.. Company insiders that have bought Lannett stock in the last two years include Jeffrey Farber, John Abt, John C Chapman, John Kozlowski, Patrick G Lepore, Samuel H Israel, and Timothy C Crew.
View insider buying and selling activity for Lannett
or or view top insider-buying stocks.

How do I buy shares of Lannett?

Shares of LCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lannett's stock price today?

One share of LCI stock can currently be purchased for approximately $0.54.

How much money does Lannett make?

Lannett has a market capitalization of $23.19 million and generates $478.78 million in revenue each year. The company earns $-363.48 million in net income (profit) each year or ($7.93) on an earnings per share basis.

How many employees does Lannett have?

Lannett employs 810 workers across the globe.

What is Lannett's official website?

The official website for Lannett is www.lannett.com.

How can I contact Lannett?

Lannett's mailing address is 9000 STATE ROAD, PHILADELPHIA PA, 19136. The company can be reached via phone at (215) 333-9000 or via fax at 215-333-9004.

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.